"10.1371_journal.pone.0061927","plos one","2013-04-23T00:00:00Z","Ralph M√∂sges; Martin Desrosiers; Pierre Arvis; Stephanie Heldner","University Hospital Cologne, Cologne, Germany; Centre Hospitalier de l‚ÄôUniversit√© de Montr√©al, Montreal, Canada; Bayer Healthcare, Loos, France; Bayer Pharma AG, Berlin, Germany","Interpretation of the results: SH PA RM MD. Conceived and designed the experiments: SH PA RM MD. Performed the experiments: SH PA RM. Analyzed the data: SH PA RM MD. Contributed reagents/materials/analysis tools: SH. Wrote the paper: SH PA RM MD.","Ralph M√∂sges has been a consultant for the following companies: AFI/Diamed, Alcon Pharma, ALK-Scherax, Allergen Therapeutics/Bencard, Allergopharma, Almirall, ASTA Medica/Meda, Sanofi/Aventis, Bayer, BGT √úberlingen, Bitop AG, Daimler AG, Essex-Pharma, Ferrero, Fresenius, HAL, Hoechst AG, Intersan, Johnson & Johnson/Janssen Research, Karl Storz Tuttlingen, Klosterfrau Cologne, Lofarma, MSD, Novartis/Leti, Optima, Pfaff AG, Philips B.V., Pierre Fabre, Promonta, Roxall, Schering-Plough Kenilworth, Schwabe, Schwarz-Pharma, Servier/IRIS, Stada, Stallerg√©nes Anthony, UCB, Ursapharm, Zyma. Ralph M√∂sges has received research grants from the following companies: AFI/Diamed, AIPrevent, Alcon Pharma, Almirall, ASTA Medica/Meda, Sanofi/Aventis, Bitop AG, Essex-Pharma, Gr√ºnenthal, HAL, Hoechst AG, Intersan, Johnson & Johnson/Janssen Research, Karl Storz Tuttlingen, Klosterfrau Cologne, Lofarma, Optima, Pierre Fabre, Promonta, Roxall, Schering-Plough Kenilworth, Servier/IRIS, Stallerg√©nes Anthony, UCB, Ursapharm, Zyma. Ralph M√∂sges has received speaker‚Äôs honoraria: AFI/Diamed, AIPrevent, ALK-Scherax, Allergen Therapeutics/Bencard, Almirall, ASTA Medica/Meda, ASTRA AB, Asche, Sanofi/Aventis, Bayer, Bionorica, Dr. Beckmann, Essex-Pharma, Fresenius, GSK, Hoechst AG, Intersan, Johnson & Johnson/Janssen Research, MSD, Novartis/Leti, Pierre Fabre, Schering-Plough Kenilworth, Schwabe, Schwarz-Pharma, Servier/IRIS, Stada, Stallerg√©nes Anthony, UCB, Yamanouchi. Pierre Arvis and Stephanie Heldner are paid employees of Bayer HealthCare (in France and Germany, respectively), the funder of this study. They are not stockholders in the company and they do not have patent applications. The Moxifloxacin used in this study is a Bayer product (Avelox¬Æ; approved for the studied indication). There are no further patents, products in development or marketed products to declare. This does not alter the authors‚Äô adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","04","Ralph M√∂sges","RM√",4,TRUE,4,3,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
